
浏览全部资源
扫码关注微信
山东中医药大学 附属医院,济南 250014
*李慧杰,博士,主治医师,从事中西医结合肿瘤防治研究,E-mail:2008lihuijie@163.com
收稿日期:2019-06-30,
网络出版日期:2019-11-04,
纸质出版日期:2020-04-20
移动端阅览
李慧杰, 胡熙文, 齐元富, 等. 代谢重编程对攻毒治法靶向治疗肺癌干细胞的影响[J]. 中国实验方剂学杂志, 2020,26(8):75-80.
Hui-jie LI, Xi-wen HU, Yuan-fu QI, et al. Effect of Metabolic Reprogramming on Toxin Eliminating Therapeutics in Targeting Lung Cancer Stem Cells[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(8): 75-80.
李慧杰, 胡熙文, 齐元富, 等. 代谢重编程对攻毒治法靶向治疗肺癌干细胞的影响[J]. 中国实验方剂学杂志, 2020,26(8):75-80. DOI: 10.13422/j.cnki.syfjx.20200423.
Hui-jie LI, Xi-wen HU, Yuan-fu QI, et al. Effect of Metabolic Reprogramming on Toxin Eliminating Therapeutics in Targeting Lung Cancer Stem Cells[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(8): 75-80. DOI: 10.13422/j.cnki.syfjx.20200423.
目的:
2
观察攻毒治法代表药物纳米雄黄靶向肺癌干细胞缺氧诱导因子(hypoxia-inducible factors
HIF)效应分子驱动代谢重编程的作用,探究肺癌干细胞、代谢重编程在肺癌转移过程中的效应机制,验证攻毒治法防治肺癌转移的有效性。
方法:
2
体外培养肺癌A549细胞,分选肺癌干细胞并鉴定。按空白组,顺铂(5 mg·L
-1
)组,纳米雄黄低、中、高剂量(100,200,400 mg·L
-1
)组分别干预,采用葡萄糖氧化酶法检测纳米雄黄对肺癌干细胞糖代谢的影响,实时荧光定量聚合酶链式反应(Real-time PCR),蛋白免疫印迹法(Western blot),酶联免疫吸附测定(ELISA)分别检测纳米雄黄对肺癌干细胞代谢重编程相关基因缺氧诱导因子-1
α
(HIF-1
α
),C-myc,p53表达的影响,对相关蛋白HIF-1
α
,磷脂酰肌醇3-激酶(PI3K),蛋白激酶B(Akt),雷帕霉素靶蛋白(mTOR)表达的影响,对相关酶葡萄糖转运蛋白1(GLUT1),丙酮酸脱氢酶激酶1(PDK1),M型丙酮酸激酶(PKM),磷酸果糖激酶(PFK),丙酮酸脱氢酶(PDH),乳酸脱氢酶(LDH)表达的影响。
结果:
2
与空白组比较,纳米雄黄可降低肺癌干细胞葡萄糖消耗,随剂量增加葡萄糖消耗不断降低,呈时间剂量依懒性(
P
<
0.01);纳米雄黄可抑制肺癌干细胞代谢重编程关键因子HIF-1
α
mRNA表达(
P
<
0.05,
P
<
0.01),并可下调C-myc mRNA,上调p53 mRNA表达(
P
<
0.05,
P
<
0.01),抑制相关蛋白PI3K,Akt,mTOR的表达(
P
<
0.05,
P
<
0.01),抑制相关酶GLUT1,PDK1,PFK,PKM,PDH,LDH的表达(
P
<
0.05,
P
<
0.01),且纳米雄黄随剂量增加调控能力不断增强。
结论:
2
攻毒治法可通过靶向HIF效应分子驱动肺癌干细胞代谢重编程,进而抑制肺癌侵袭转移。
Objective:
2
To observe the effect of realgar nanoparticles (a representative drug in toxin eliminating therapeutics) targeting hypoxia-inducible factors (HIF)
which act as effector molecules on metabolic reprogramming of lung cancer stem cells
and to explore the effect mechanism of lung cancer stem cells and metabolic reprogramming in the process of lung cancer metastasis
so as to verify the effectiveness of toxin eliminating therapeutics in the prevention and treatment of lung cancer metastasis.
Method:
2
Lung cancer A549 cells were cultured
in vitro
and lung cancer stem cells were then identified and selected. The stem cells were divided into blank control group
cisplatin group (5 mg·L
-1
)
realgar nanoparticles low
medium and high dose groups (100
200
400 mg·L
-1
). After intervention
glucose oxidase method was used to detect the effect of realgar nanoparticles on the glucose metabolism of lung cancer stem cells
real-time polymerase chain reaction (Real-time PCR) was used to detect the mRNA expression levels of hypoxia-inducible factors-1
α
(HIF-1
α
)
C-myc and p53
while Western blot was used to detect the expression of related proteins HIF-1
α
phosphatidylinositol 3-kinase (PI3K)
protein kinase B (Akt) and mammalian target of rapamycin (mTOR)
and enzyme linked immunosorbent assay (ELISA) was used to detect the glucose transporter 1 (GLUT1)
pyruvate dehydrogenase kinase 1 (PDK1)
pyruvate kinase M (PKM)
phosphofructokinase(PFK)
pyruvate dehydrogenase (PDH) and lactic dehydrogenase (LDH) expression.
Result:
2
As compared with the blank control group
realgar nanoparticles can reduce the glucose consumption of lung cancer stem cells
and the glucose consumption was reduced with the increase of dose in a time-and dose-dependent manner (
P
<
0.01). Realgar nanoparticles can inhibit the mRNA expression of HIF-1
α
a key factor in metabolic reprogramming of lung cancer stem cells (
P
<
0.05
P
<
0.01)
down-regulated C-myc mRNA and up-regulated the p53 mRNA expression (
P
<
0.05
P
<
0.01)
down-regulated protein expressions of PI3K
Akt
mTOR(
P
<
0.05
P
<
0.01)
and inhibited the expression of related enzymes GLUT1
PDK1
PFK
PKM
PDH
and LDH levels (
P
<
0.05
P
<
0.01). With the increase of dose
the regulation and control ability of realgar nanoparticles gradually increased.
Conclusion:
2
Toxin eliminating therapeutics can drive the metabolic reprogramming of lung cancer stem cells by targeting HIF effector molecule
and then inhibit the invasion and metastasis of lung cancer.
P JAGUST , B LUXÁN-DELAGDO , B PAREJO-ALOSO , et al . Metabolism-based therapeutic strategies targeting cancer stem cells [J]. Front Pharmacol , 2019 , 10 ( 1 ): 203 - 212 .
L CORTES-DERICKS , D GALETTA . The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges [J]. Cell Oncol , 2019 , 28 ( 7 ): 13402 - 13415 .
N GANDHI , M D GOKUL . Metabolic reprogramming in breast cancer and its therapeutic implications [J]. Cells , 2019 , 8 ( 2 ): 89 - 103 .
李慧杰 , 齐元富 , 李秀荣 . 缺氧诱导因子1在肿瘤进程中的作用机制研究 [J]. 现代肿瘤医学 , 2018 , 26 ( 18 ): 2979 - 2981 .
J QIN , Y LIU , Y LU , et al . Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovariancancer cells by upregulating SIRT1 expression [J]. Sci Rep , 2017 , 7 ( 1 ): 10592 - 10599 .
J MATHEWS , P M DAVY , L H GARDNER , et al . Stem cells, telomerase regulation and the hypoxic state [J]. Front Biosci , 2016 , 21 ( 1 ): 303 - 315 .
A NAGAO , M KOBAYASHI , S KOYASU , et al . HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance [J]. Int J Mol Sci , 2019 , 20 ( 2 ): 238 - 252 .
L ZHANG , Y YANG , L CHAI , et al . FRK plays an oncogenic role in nonsmall cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming [J]. Intern J Can , 2019 , 145 ( 5 ): 1169 - 1182 .
孙海超 , 朴海龙 , 齐欢 , 等 . 基于代谢组学的多西他赛调控肺癌细胞代谢重编程研究 [J]. 中国肺癌杂志 , 2019 , 22 ( 4 ): 208 - 215 .
卢建峰 , 黄静 , 肖桦 , 等 . 中药治疗肺癌干细胞研究进展 [J]. 中药与临床 , 2018 , 9 ( 4 ): 63 - 66 .
李晓芸 , 卞卡 . 中药干预肿瘤Warburg效应的研究进展 [J]. 上海中医药大学学报 , 2017 , 31 ( 1 ): 87 - 99 .
余功 , 陈江涛 , 胡桥 , 等 . 清燥救肺汤对荷Lewis小鼠肺癌细胞糖酵解关键限速酶HK2,PFK2,PKM2的影响 [J]. 中国实验方剂学杂志 , 2019 , doi: 10.13422/j.cnki.syfjx.20191325 http://dx.doi.org/10.13422/j.cnki.syfjx.20191325 .
齐元富 , 李慧杰 , 刘寨东 . 纳米雄黄对肺癌A549细胞增殖影响及其机制的探讨 [J]. 中华肿瘤防治杂志 , 2013 , 20 ( 1 ): 27 - 30 .
齐元富 , 李慧杰 , 聂奔 . 纳米雄黄对人皮肤鳞状细胞癌A431细胞株增殖抑制及诱导凋亡作用的研究 [J]. 中国实验方剂学杂志 , 2013 , 19 ( 4 ): 187 - 191 .
李慧杰 , 齐元富 , 李秀荣 , 等 . 芪连扶正胶囊干预肺癌干细胞白细胞介素-10、转化生长因子- β 1 表达对免疫重塑的影响 [J]. 世界中医药 , 2018 , 13 ( 18 ): 1968 - 1971 .
M SHAN , D DAI , A VUDEM , et al . Multi-scale computational study of the Warburg effect, reverse warburg effect and glutamine addiction in solid tumors [J]. PLoS Computa Biol , 2018 , 14 ( 12 ): 1371 - 1384 .
E RED , J T MURRAY , A R TEE . Oncogenic signalling through mechanistic target of rapamycin (mTOR): a driver of metabolic transformation and cancer progression [J]. Cancers:Basel , 2018 , 10 ( 1 ): 3390 - 3398 .
L SCHITO , S REY . Cell-autonomous metabolic reprogramming in hypoxia [J]. Trends Cell Biol , 2017 , 27 ( 17 ): 30197 - 30206 .
C CHEN , Q TANG , Y ZHANG , et al . Metabolic reprogramming by HIF-1 activation enhances survivability of human adipose-derived stem cells in ischaemic microenvironments [J]. Cell Prolif , 2017 , 50 ( 5 ): 12363 - 12371 .
M SHIBATA , M O HOQUE . Targeting cancer stem cells: a strategy for effective eradication of cancer [J]. Cancers:Basel , 2019 , 11 ( 5 ): 732 - 745 .
李慧杰 , 齐元富 , 李秀荣 . 肺癌干细胞与肺癌转移相关机制的研究进展 [J]. 中国肿瘤 , 2017 , 26 ( 10 ): 798 - 801 .
J A MENENDEZ , J JOVEN , S CUFÍ , et al . The warburg effect version 2.0: metabolic reprogramming of cancer stem cells [J]. Cell Cycle , 2013 , 12 ( 8 ): 1166 - 1179 .
李慧杰 , 齐元富 , 李秀荣 . 基于癌毒理论探讨攻毒治法抗肿瘤转移 [J]. 中医药信息 , 2018 , 35 ( 4 ): 81 - 83 .
裴可 , 冯慧超 , 郑文利 , 等 . 纳米雄黄抗肿瘤的药理毒理研究及临床应用 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 5 ): 214 - 219 .
齐元富 , 李慧杰 , 于连洋 . 纳米雄黄干预肺癌A549细胞对血管内皮生长因子及缺氧诱导因子-1表达的影响 [J]. 中国老年学杂志 , 2015 , 35 ( 3 ): 27 - 30 .
0
浏览量
17
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621